Skip to content

Celiac Disease in Childhood-Adulthood Transition

Celiac Disease in Childhood-Adulthood Transition (CeliCAT)

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05084937
Acronym
CeliCAT
Enrollment
400
Registered
2021-10-20
Start date
2021-11-01
Completion date
2026-12-31
Last updated
2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac Disease, Celiac Disease in Children, Diet, Gluten-Free, Follow-up, Transition of Care

Keywords

celiac disease, adolescents, transition, follow-up, gluten-free diet, quality of life, health, symptoms

Brief summary

Aims of this study are to evaluate adolescents with celiac disease during their transition from pediatrics to adult care, and to develop better healthcare follow-up practices.

Detailed description

Celiac disease is one of the most common chronic gastrointestinal diseases affecting 1-3% of population worldwide. It is treated with life-long and strict gluten-free diet. When dietary treatment is successful, prognosis of pediatric patients seems to be excellent whereas ongoing predisposition to gluten may increase the risk even to permanent complications. However, gluten-free diet may cause burden and restrictions in everyday life impairing quality of life. Regular follow-up is recommended to support the treatment and to detect early possible comorbidities and complications, but, in practice, patients are often lost to follow-up. Studies about the significance of follow-up and its optimal implementation are scarce. Pediatric patients form a special group here as they may not even remember the reason for the diagnosis if it was set in early childhood, and the education about the disease and its treatment are often given primarily to the caregivers. Responsibility of the treatment shifts to patients themselves in adolescence at the same time with other significant changes in life and they have more often challenges with gluten-free diet than other patients. Despite this, studies about the transition from pediatrics to adult-care are very few. This study evaluates 13-19 years old patients diagnosed with celiac disease in childhood (\<16 years of age) and compares them to adolescents without celiac disease in selected variables. Study focuses on healthcare follow-up practices and pilot a CeliCAT transition form in a randomized, controlled study design. The main hypothesis is that structured follow-up and transition of pediatric patients to adult care predicts better health, quality of life and adherence to the dietary treatment later in life. Data is collected with physical examination, questionnaires and with blood and urine samples. Follow-up is arranged at one and three years from the first visit.

Interventions

OTHERCeliCAT form

Systematic summary to support transition

Sponsors

Tampere University
CollaboratorOTHER
Kuopio University Hospital
CollaboratorOTHER
Turku University Hospital
CollaboratorOTHER_GOV
Seinajoki Central Hospital
CollaboratorOTHER
South Carelia Central Hospital
CollaboratorOTHER
Tampere University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Structured transition form is used with 50% of the study patients

Eligibility

Sex/Gender
ALL
Age
13 Years to 19 Years
Healthy volunteers
No

Inclusion criteria

* verified celiac disease diagnosis in childhood (\<16 years of age) * age 13-19 years at recruitment * Finnish-speaking

Exclusion criteria

* disease or condition preventing the completing of the study questionnaire Inclusion criteria for controls * no celiac disease diagnosis * age 13-19 years at recruitment * Finnish-speaking

Design outcomes

Primary

MeasureTime frameDescription
Adherence to a gluten-free dietAt the onset of the studyAssessed with questionnaire, celiac autoantibodies and urine GIP
Change in adherence to a gluten-free dietAfter 1 and 3 yearsAssessed with questionnaire, celiac autoantibodies and urine GIP
Transition readinessAt the onset of the studyAssessed with questionnaire
Change in transition readinessAfter 1 and 3 yearsAssessed with questionnaire

Secondary

MeasureTime frameDescription
Quality of lifeAt the onset of the studyAssessed with questionnaire
Change in quality of lifeAfter 1 and 3 yearsAssessed with questionnaire
General health and health concernsAt the onset of the studyAssessed with questionnaire
Abnormalities in follow-up laboratory evaluationsAt the onset of the studyAssessed with blood sample
Abnormalities in physical examinationAt the onset of the studyAssessed with medical examination
CostsAt the onset of the studyAssessed with questionnaire
Change in general health and health concernsAfter 1 and 3 yearsAssessed with questionnaire
SymptomsAt the onset of the studyAssessed with questionnaire
Change in symptomsAfter 1 and 3 yearsAssessed with questionnaire

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026